MCO Membrane Efficiency in Septic Shock Patients

Randomized Blinded Controlled Pilot Study on Clinical Assessment of Continuous Hemodialysis With a High Molecular Flux Membrane

This is a monocentre randomized pilot study. All patients received two consecutive RRT: CVVHD with MCO filter (Ultraflux® EMiC®2) and post-Continuous Veno-Venous Hemodiafiltration (CVVHDF) with HFF(AV1000S®) in a controlled randomized (1:1) blinded manner. Crossover randomized to sequence (A+B or B+A) for 48 h total without washout.

This is a monocentre randomized pilot study. All patients received CVVHD with MCO filter (Ultraflux® EMiC®2) and post-Continuous Veno-Venous Hemodiafiltration (CVVHDF) with HFF(AV1000S®) in a controlled randomized (1:1) blinded manner. Crossover randomized to sequence (A+B or B+A) for 48 h total without washout.

The efficiency of the filters for small and middle molecules was compared in septic shock patients with AKI stage 3.

Inclusion Criteria:

• Age > 18 years;
• septic shock according to ACCP/SCCM criteria
• AKI KDIGO stage 3
• clinical decision to begin citrate based-RRT for at least 48 hours
• Hb >= 9 g/dL
• Obtain the informed consent

Exclusion Criteria:

• Pre-existing chronic renal insufficiency
• Weight > 125 kg Life expectancy <24 hr
• Declared do Not Resuscitate or Comfort Measures
• Platelets < 20 [10^3/ul] or active bleeding
• Pregnancy
• Contraindication to citrate